Amedeo Smart

Free Medical Literature Service

 

Amedeo

Multiple Sclerosis
  Free Subscription

Articles published in
J Neurol Neurosurg Psychiatry
    April 2024
  1. ABDEL-MANNAN O, Champsas D, Tur C, Lee V, et al
    Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course.
    J Neurol Neurosurg Psychiatry. 2024;95:426-433.
    >> Share

  2. MAHLER MR, Magyari M, Pontieri L, Elberling F, et al
    Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study.
    J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333265.
    >> Share

  3. DEKEYSER C, Hautekeete M, Cambron M, Van Pesch V, et al
    Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
    J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333307.
    >> Share

    March 2024
  4. VERSTEGEN NJM, Hagen RR, Kreher C, Kuijper LH, et al
    T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
    J Neurol Neurosurg Psychiatry. 2024 Mar 28:jnnp-2023-332224.
    >> Share

  5. KALINCIK T, Sharmin S, Roos I, Massey J, et al
    Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Mar 27:jnnp-2023-332790.
    >> Share

  6. JONS D, Grut V, Bergstrom T, Zetterberg H, et al
    Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.
    J Neurol Neurosurg Psychiatry. 2024;95:325-332.
    >> Share

  7. FOONG YC, Merlo D, Gresle M, Buzzard K, et al
    Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
    J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332883.
    >> Share

  8. JING J, Zhang Z, Su L, Gao C, et al
    Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T MRI.
    J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332566.
    >> Share

    February 2024
  9. POZZILLI V, Haggiag S, Di Filippo M, Capone F, et al
    Incidence and determinants of seizures in multiple sclerosis: a meta-analysis of randomised clinical trials.
    J Neurol Neurosurg Psychiatry. 2024 Feb 21:jnnp-2023-332996.
    >> Share

  10. IOANNIDIS JP
    Therapeutic interventions increasing seizure risk in multiple sclerosis: resolving discordant meta-analyses.
    J Neurol Neurosurg Psychiatry. 2024 Feb 21:jnnp-2024-333329.
    >> Share

    January 2024
  11. SIGNORI A, Ponzano M, Kalincik T, Ozakbas S, et al
    Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.
    J Neurol Neurosurg Psychiatry. 2024 Jan 19:jnnp-2023-332603.
    >> Share

  12. JOHANSSON E, Alfredsson L, Strid P, Kockum I, et al
    Head trauma results in manyfold increased risk of multiple sclerosis in genetically susceptible individuals.
    J Neurol Neurosurg Psychiatry. 2024 Jan 11:jnnp-2023-332643.
    >> Share

    December 2023
  13. ELSBERND P, Cacciaguerra L, Krecke KN, Chen JJ, et al
    Cerebral enhancement in MOG antibody-associated disease.
    J Neurol Neurosurg Psychiatry. 2023;95:14-18.
    >> Share

  14. ZIVADINOV R, Pei J, Clayton D, Goldman DE, et al
    Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study.
    J Neurol Neurosurg Psychiatry. 2023 Dec 6:jnnp-2023-332573.
    >> Share

    November 2023
  15. ALBA-ARBALAT S, Solana E, Lopez-Soley E, Camos-Carreras A, et al
    Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Nov 21:jnnp-2023-332332.
    >> Share

  16. KOCH M
    Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    J Neurol Neurosurg Psychiatry. 2023 Nov 14:jnnp-2023-332758.
    >> Share

  17. TOOROP AA, van Lierop ZY, Gelissen LM, Hoitsma E, et al
    Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    J Neurol Neurosurg Psychiatry. 2023 Nov 14:jnnp-2023-332119.
    >> Share

  18. FISSOLO N, Benkert P, Sastre-Garriga J, Mongay-Ochoa N, et al
    Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Nov 8:jnnp-2023-332251.
    >> Share

  19. PALMER AJ, Zhao T, Taylor BV, van der Mei I, et al
    Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting.
    J Neurol Neurosurg Psychiatry. 2023 Nov 2:jnnp-2023-332161.
    >> Share

    October 2023
  20. CAMPBELL JA, van der Mei I, Taylor BV, Palmer AJ, et al
    Using qualitative free-text data to investigate the lived experience of the COVID-19 pandemic for a large cohort of Australians with different multiple sclerosis related disability levels.
    J Neurol Neurosurg Psychiatry. 2023 Oct 26:jnnp-2022-330755.
    >> Share

  21. MONTINI F, Nozzolillo A, Tedone N, Mistri D, et al
    COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study.
    J Neurol Neurosurg Psychiatry. 2023 Oct 19:jnnp-2023-332073.
    >> Share

  22. MAIWORM M, Hamid C, Wagner M, Noth U, et al
    Multiparametric quantitative MRI reveals progressive cortical damage over time in clinically stable relapsing-remitting MS.
    J Neurol Neurosurg Psychiatry. 2023;94:786-791.
    >> Share

    September 2023
  23. RUGGIERI S, Prosperini L, Al-Araji S, Annovazzi PO, et al
    Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
    J Neurol Neurosurg Psychiatry. 2023 Sep 29:jnnp-2023-331920.
    >> Share

  24. SILFVERBERG T, Zjukovskaja C, Ljungman P, Nahimi A, et al
    Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
    J Neurol Neurosurg Psychiatry. 2023 Sep 25:jnnp-2023-331864.
    >> Share

  25. YUSUF FLA, Asaf A, Marrie RA, Li P, et al
    Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada's population.
    J Neurol Neurosurg Psychiatry. 2023 Sep 21:jnnp-2023-331991.
    >> Share

    August 2023
  26. GAY MC, Cassedanne F, Barbot F, Vaugier I, et al
    Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care.
    J Neurol Neurosurg Psychiatry. 2023 Aug 30:jnnp-2023-331537.
    >> Share

  27. LONGINETTI E, Englund S, Burman J, Fink K, et al
    Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.
    J Neurol Neurosurg Psychiatry. 2023 Aug 9:jnnp-2023-331784.
    >> Share

  28. MASCARENAS-GARCIA M, Rivero-de-Aguilar A, Perez-Rios M, Ruano-Ravina A, et al
    Best practices in phase III clinical trials on DMTs for multiple sclerosis: a systematic analysis and appraisal of published trials.
    J Neurol Neurosurg Psychiatry. 2023 Aug 4:jnnp-2023-331733.
    >> Share

  29. HABEN S, Ciplea AI, Tokic M, Timmesfeld N, et al
    Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Aug 3:jnnp-2023-331525.
    >> Share

    July 2023
  30. LAUERER M, McGinnis J, Bussas M, El Husseini M, et al
    Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 26:jnnp-2023-331799.
    >> Share

  31. KAPALI A, Daltveit AK, Myhr KM, Bjornevik K, et al
    Childbirth delivery mode and the risk of multiple sclerosis: a prospective population-based study.
    J Neurol Neurosurg Psychiatry. 2023 Jul 21:jnnp-2023-331241.
    >> Share

  32. JEANTIN L, Abdi B, Soulie C, Sterlin D, et al
    Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
    J Neurol Neurosurg Psychiatry. 2023 Jul 21:jnnp-2023-331770.
    >> Share

  33. MOROZUMI T, Preziosa P, Meani A, Albergoni M, et al
    Influence of cardiorespiratory fitness and MRI measures of neuroinflammation on hippocampal volume in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 19:jnnp-2023-331482.
    >> Share

  34. COLATO E, Prados F, Stutters J, Bianchi A, et al
    Networks of microstructural damage predict disability in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 19:jnnp-2022-330203.
    >> Share

  35. ROSENKRANZ SC, Gutmann L, Has Silemek AC, Dorr M, et al
    Visual function resists early neurodegeneration in the visual system in primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 11:jnnp-2023-331183.
    >> Share

  36. DZAU W, Sharmin S, Patti F, Izquierdo G, et al
    Risk of secondary progressive multiple sclerosis after early worsening of disability.
    J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331748.
    >> Share

  37. DIOUF I, Malpas CB, Sharmin S, Roos I, et al
    Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
    J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331499.
    >> Share

    June 2023
  38. MARTINEZ-HERAS E, Solana E, Vivo F, Lopez-Soley E, et al
    Diffusion-based structural connectivity patterns of multiple sclerosis phenotypes.
    J Neurol Neurosurg Psychiatry. 2023 Jun 15:jnnp-2023-331531.
    >> Share

  39. HOUZEN H, Kano T, Kondo K, Takahashi T, et al
    Prevalence, incidence and clinical features of neuromyelitis optica spectrum disorders in northern Japan.
    J Neurol Neurosurg Psychiatry. 2023;94:494-495.
    >> Share

    May 2023
  40. STRIJBIS EM, Coerver E, Mostert J, van Kempen ZLE, et al
    Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 May 12:jnnp-2022-330887.
    >> Share

  41. SARASTE M, Matilainen M, Vuorimaa A, Laaksonen S, et al
    Association of serum neurofilament light with microglial activation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 May 2:jnnp-2023-331051.
    >> Share

    April 2023
  42. NOVAK F, Bajwa HM, Coia JE, Nilsson AC, et al
    Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
    J Neurol Neurosurg Psychiatry. 2023 Apr 25:jnnp-2022-330757.
    >> Share

  43. LEPPERT D, Watanabe M, Schaedelin S, Piehl F, et al
    Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Apr 19:jnnp-2022-330796.
    >> Share

  44. HARDING-FORRESTER S, Roos I, Nguyen AL, Malpas CB, et al
    Disability accrual in primary and secondary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Apr 17:jnnp-2022-330726.
    >> Share

  45. MOCCIA M, Affinito G, Fumo MG, Giordana R, et al
    Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020.
    J Neurol Neurosurg Psychiatry. 2023 Apr 17:jnnp-2022-330883.
    >> Share

    March 2023
  46. WU J, Olsson T, Hillert J, Alfredsson L, et al
    Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression.
    J Neurol Neurosurg Psychiatry. 2023 Mar 31:jnnp-2022-330848.
    >> Share

  47. MARGONI M, Preziosa P, Storelli L, Gueye M, et al
    Paramagnetic rim and core sign lesions in paediatric multiple sclerosis patients.
    J Neurol Neurosurg Psychiatry. 2023 Mar 29:jnnp-2022-331027.
    >> Share

  48. RIVERO-DE-AGUILAR A, Perez-Rios M, Ruano-Ravina A, Candal-Pedreira C, et al
    Evidence of publication bias in multiple sclerosis clinical trials: a comparative analysis of published and unpublished studies registered in ClinicalTrials.gov.
    J Neurol Neurosurg Psychiatry. 2023 Mar 28:jnnp-2023-331132.
    >> Share

  49. LEADBETTER R, MacAskill M, Myall DJ, Taylor BV, et al
    Multiple sclerosis mortality in New Zealand: a nationwide prospective study.
    J Neurol Neurosurg Psychiatry. 2023 Mar 7:jnnp-2022-330582.
    >> Share

    February 2023
  50. SCHUBERT C, Steinberg L, Peper J, Ramien C, et al
    Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2023 Feb 20:jnnp-2022-330533.
    >> Share

  51. LIN X, Yang Y, Fuh-Ngwa V, Yin X, et al
    Genetically determined serum serine level has a novel causal effect on multiple sclerosis risk and predicts disability progression.
    J Neurol Neurosurg Psychiatry. 2023 Feb 2:jnnp-2022-330259.
    >> Share

  52. NASR Z, Schoeps VA, Ziaei A, Virupakshaiah A, et al
    Gene-environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures.
    J Neurol Neurosurg Psychiatry. 2023 Feb 1:jnnp-2022-330713.
    >> Share

    January 2023
  53. TOOROP AA, Hogenboom L, Bloem K, Kocyigit M, et al
    Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jan 24:jnnp-2022-330793.
    >> Share

  54. AKERSTEDT T, Olsson T, Alfredsson L, Hedstrom AK, et al
    Insufficient sleep during adolescence and risk of multiple sclerosis: results from a Swedish case-control study.
    J Neurol Neurosurg Psychiatry. 2023 Jan 23:jnnp-2022-330123.
    >> Share

  55. SASTRE-GARRIGA J, Rovira A, Garcia-Vidal A, Carbonell-Mirabent P, et al
    Spinal cord reserve in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jan 23:jnnp-2022-330613.
    >> Share

  56. MENCULINI G, Mancini A, Gaetani L, Bellingacci L, et al
    Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction.
    J Neurol Neurosurg Psychiatry. 2023 Jan 18:jnnp-2022-329806.
    >> Share

  57. TOOROP AA, van Kempen ZLE, Steenhuis M, Nielsen J, et al
    Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jan 13:jnnp-2022-330467.
    >> Share

  58. SIGNORI A, Lorscheider J, Vukusic S, Trojano M, et al
    Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
    J Neurol Neurosurg Psychiatry. 2023;94:23-30.
    >> Share

    December 2022
  59. VAN KEMPEN ZLE, Stalman EW, Steenhuis M, Kummer LYL, et al
    SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Dec 23:jnnp-2022-330100.
    >> Share

  60. SMITH KA, Piehl F, Olsson T, Alfredsson L, et al
    Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study.
    J Neurol Neurosurg Psychiatry. 2022 Dec 20:jnnp-2022-329886.
    >> Share

  61. AIELLO A, Coppola A, Ruggieri S, Farroni C, et al
    Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.
    J Neurol Neurosurg Psychiatry. 2022 Dec 15:jnnp-2022-330175.
    >> Share

  62. HE A, Spelman T, Manouchehrinia A, Ciccarelli O, et al
    Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study.
    J Neurol Neurosurg Psychiatry. 2022 Dec 7:jnnp-2022-330169.
    >> Share

    November 2022
  63. MONTALBAN X, Wallace D, Genovese MC, Tomic D, et al
    Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
    J Neurol Neurosurg Psychiatry. 2022 Nov 23:jnnp-2022-328799.
    >> Share

  64. DILWALI S, Mark I, Waubant E
    MRI lesions can often precede trigeminal neuralgia symptoms by years in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Nov 17. pii: jnnp-2022-330172.
    >> Share

  65. MARGONI M, Gueye M, Meani A, Pagani E, et al
    Choroid plexus enlargement in paediatric multiple sclerosis: clinical relevance and effect of sex.
    J Neurol Neurosurg Psychiatry. 2022 Nov 9. pii: jnnp-2022-330343.
    >> Share

  66. COMABELLA M, Tintore M, Sao Aviles A, Carbonell-Mirabent P, et al
    Increased cytomegalovirus immune responses at disease onset are protective in the long-term prognosis of patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Nov 7. pii: jnnp-2022-330205.
    >> Share

  67. HARDING KE, Ingram G, Tallantyre EC, Joseph F, et al
    Contemporary study of multiple sclerosis disability in South East Wales.
    J Neurol Neurosurg Psychiatry. 2022 Nov 3. pii: jnnp-2022-330013.
    >> Share

  68. LUTFULLIN I, Eveslage M, Bittner S, Antony G, et al
    Association of obesity with disease outcome in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Nov 1. pii: jnnp-2022-329685.
    >> Share

    October 2022
  69. ZHU C, Zhou Z, Roos I, Merlo D, et al
    Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Oct 19. pii: jnnp-2022-330104.
    >> Share

  70. CAROTENUTO A, Valsasina P, Preziosa P, Mistri D, et al
    Monoaminergic network abnormalities: a marker for multiple sclerosis-related fatigue and depression.
    J Neurol Neurosurg Psychiatry. 2022 Oct 13. pii: jnnp-2022-330109.
    >> Share

  71. WEI R, Xu X, Duan Y, Zhang N, et al
    Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Oct 10. pii: jnnp-2022-329680.
    >> Share

    September 2022
  72. LANDI D, Bovis F, Grimaldi A, Annovazzi PO, et al
    Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Sep 30. pii: jnnp-2022-329657.
    >> Share

  73. SHARMIN S, Malpas CB, Roos I, Diouf I, et al
    Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry.
    J Neurol Neurosurg Psychiatry. 2022 Sep 30. pii: jnnp-2022-329713.
    >> Share

  74. ROCCA MA, Valsasina P, Meani A, Gobbi C, et al
    Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study.
    J Neurol Neurosurg Psychiatry. 2022 Sep 28. pii: jnnp-2022-329854.
    >> Share

  75. WILLUMSEN JS, Grytten N, Aarseth J, Myklebust TA, et al
    Mortality and cause of death in multiple sclerosis in western Norway 1950-2021: a registry-based linkage study.
    J Neurol Neurosurg Psychiatry. 2022 Sep 12. pii: jnnp-2022-329169.
    >> Share

    August 2022
  76. MARRIE RA, Fisk JD, Walld R, Bolton JM, et al
    Prescription opioid use in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Aug 26. pii: jnnp-2022-329508.
    >> Share

  77. CHO EB, Yeo Y, Jung JH, Jeong SM, et al
    Risk of stroke in multiple sclerosis and neuromyelitis optic spectrum disorder: a Nationwide cohort study in South Korea.
    J Neurol Neurosurg Psychiatry. 2022 Aug 26. pii: jnnp-2022-329628.
    >> Share

  78. BOSE G, Healy BC, Barro C, Glanz BI, et al
    Younger age at multiple sclerosis onset is associated with worse outcomes at age 50.
    J Neurol Neurosurg Psychiatry. 2022 Aug 11. pii: jnnp-2022-329353.
    >> Share

  79. KVISTAD SAS, Burman J, Lehmann AK, Tolf A, et al
    Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT.
    J Neurol Neurosurg Psychiatry. 2022;93:844-848.
    >> Share

    July 2022
  80. CHEN J, Diouf I, Taylor BV, Kalincik T, et al
    Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jul 28. pii: jnnp-2022-329223.
    >> Share

  81. KWON S, Jung SY, Han KD, Jung JH, et al
    Risk of Parkinson's disease in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea.
    J Neurol Neurosurg Psychiatry. 2022 Jul 28. pii: jnnp-2022-329389.
    >> Share

  82. LASLETT LL, Honan C, Turner JA, Dagnew B, et al
    Poor sleep and multiple sclerosis: associations with symptoms of multiple sclerosis and quality of life.
    J Neurol Neurosurg Psychiatry. 2022 Jul 27. pii: jnnp-2022-329227.
    >> Share

  83. ROD BE, Torkildsen O, Myhr KM, Bo L, et al
    Safety of breast feeding during rituximab treatment in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jul 25. pii: jnnp-2022-329545.
    >> Share

  84. MEYER-ARNDT L, Braun J, Fauchere F, Vanshylla K, et al
    SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
    J Neurol Neurosurg Psychiatry. 2022 Jul 14. pii: jnnp-2022-329395.
    >> Share

    June 2022
  85. ABDELHAK A, Cordano C, Boscardin WJ, Caverzasi E, et al
    Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jun 16. pii: jnnp-2022-329221.
    >> Share

  86. WANDALL-HOLM MF, Buron MD, Kopp TI, Thielen K, et al
    Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jun 10. pii: jnnp-2022-329058.
    >> Share

  87. ETEMADIFAR M, Nouri H, Pitzalis M, Idda ML, et al
    Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2022 Jun 10. pii: jnnp-2022-329123.
    >> Share

  88. LIE IA, Kacar S, Wesnes K, Brouwer I, et al
    Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study.
    J Neurol Neurosurg Psychiatry. 2022 Jun 1. pii: jnnp-2021-328568.
    >> Share

    May 2022
  89. MARGONI M, Pagani E, Meani A, Storelli L, et al
    Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study.
    J Neurol Neurosurg Psychiatry. 2022 May 17. pii: jnnp-2022-328908.
    >> Share

  90. SIMPSON-YAP S, Atvars R, Blizzard L, van der Mei I, et al
    Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia.
    J Neurol Neurosurg Psychiatry. 2022 May 16. pii: jnnp-2022-328932.
    >> Share

    April 2022
  91. COMABELLA M, Sastre-Garriga J, Carbonell-Mirabent P, Fissolo N, et al
    Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Apr 29. pii: jnnp-2022-329020.
    >> Share

  92. PROSPERINI L, Lucchini M, Ruggieri S, Tortorella C, et al
    Shift of multiple sclerosis onset towards older age.
    J Neurol Neurosurg Psychiatry. 2022 Apr 27. pii: jnnp-2022-329049.
    >> Share

  93. SUGIYAMA A, Kuwabara S
    Microstructural changes in the normal appearance cerebral cortex of multiple sclerosis detected by an advanced diffusion MRI technique.
    J Neurol Neurosurg Psychiatry. 2022 Apr 25. pii: jnnp-2021-328089.
    >> Share

  94. BRENTON JN, Lehner-Gulotta D, Woolbright E, Banwell B, et al
    Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits.
    J Neurol Neurosurg Psychiatry. 2022 Apr 13. pii: jnnp-2022-329074.
    >> Share

  95. MAGYARI M, Koch-Henriksen N
    Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Apr 7. pii: jnnp-2022-328994.
    >> Share

  96. EID K, Torkildsen O, Aarseth J, Aalstad M, et al
    Association of adverse childhood experiences with the development of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Apr 4. pii: jnnp-2021-328700.
    >> Share

    March 2022
  97. WILLIAMS T, Mishra R, Bharkhada B, Shields A, et al
    Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study.
    J Neurol Neurosurg Psychiatry. 2022 Mar 10. pii: jnnp-2021-328340.
    >> Share

    February 2022
  98. RAUBER S, Korsen M, Huntemann N, Rolfes L, et al
    Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
    J Neurol Neurosurg Psychiatry. 2022 Feb 22. pii: jnnp-2021-328197.
    >> Share

    January 2022
  99. MASUDA H, Mori M, Hirano S, Uzawa A, et al
    Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    J Neurol Neurosurg Psychiatry. 2022;93:32-40.
    >> Share

    November 2021
  100. PREZIOSA P, Pagani E, Bonacchi R, Cacciaguerra L, et al
    In vivo detection of damage in multiple sclerosis cortex and cortical lesions using NODDI.
    J Neurol Neurosurg Psychiatry. 2021 Nov 19. pii: jnnp-2021-327803.
    >> Share

  101. NIJ BIJVANK J, Uitdehaag BMJ, Petzold A
    Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics.
    J Neurol Neurosurg Psychiatry. 2021 Nov 11. pii: jnnp-2021-327468.
    >> Share

    October 2021
  102. KONIG M, Lorentzen AR, Torgauten HM, Tran TT, et al
    Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
    J Neurol Neurosurg Psychiatry. 2021 Oct 20. pii: jnnp-2021-327612.
    >> Share

  103. MASUDA H, Mori M, Kuwabara S
    Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Oct 19. pii: jnnp-2021-326821.
    >> Share

  104. SIMPSON-YAP S
    Relationships with MS not unique to relapsing-onset phenotypes.
    J Neurol Neurosurg Psychiatry. 2021;92:1029-1030.
    >> Share

    September 2021
  105. TAYLOR BV
    Sequencing of and escalation paradigms for MS therapies: time for a rethink?
    J Neurol Neurosurg Psychiatry. 2021;92:913.
    >> Share

    August 2021
  106. DI FILIPPO M, Cordioli C, Malucchi S, Annovazzi P, et al
    mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Aug 18. pii: jnnp-2021-327200.
    >> Share

  107. MONSCHEIN T, Hartung HP, Zrzavy T, Barnett M, et al
    Vaccination and multiple sclerosis in the era of the COVID-19 pandemic.
    J Neurol Neurosurg Psychiatry. 2021 Aug 5. pii: jnnp-2021-326839.
    >> Share

  108. LOUAPRE C, Ibrahim M, Maillart E, Abdi B, et al
    Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
    J Neurol Neurosurg Psychiatry. 2021 Aug 2. pii: jnnp-2021-326904.
    >> Share

    July 2021
  109. MARGONI M, Villani U, Finos L, Franciotta S, et al
    Neurite orientation dispersion and density imaging discloses early changes in the normal-appearing white matter in paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Jul 16. pii: jnnp-2021-326355.
    >> Share

  110. DUAN Y, Zhuo Z, Li H, Tian DC, et al
    Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
    J Neurol Neurosurg Psychiatry. 2021;92:709-716.
    >> Share

    June 2021
  111. WANG C, Barton J, Kyle K, Ly L, et al
    Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy.
    J Neurol Neurosurg Psychiatry. 2021 Jun 29. pii: jnnp-2021-326164.
    >> Share

    May 2021
  112. HEDSTROM AK, Hillert J, Olsson T, Alfredsson L, et al
    Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 May 13. pii: jnnp-2020-325688.
    >> Share

    April 2021
  113. COLATO E, Stutters J, Tur C, Narayanan S, et al
    Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes.
    J Neurol Neurosurg Psychiatry. 2021 Apr 20. pii: jnnp-2020-325610.
    >> Share

    March 2021
  114. HAIDER L, Chung K, Birch G, Eshaghi A, et al
    Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up.
    J Neurol Neurosurg Psychiatry. 2021 Mar 30. pii: jnnp-2020-325421.
    >> Share

  115. PFEUFFER S, Ruck T, Pul R, Rolfes L, et al
    Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
    J Neurol Neurosurg Psychiatry. 2021 Mar 12. pii: jnnp-2020-325304.
    >> Share

  116. HEDSTROM AK, Hillert J, Brenner N, Butt J, et al
    DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies.
    J Neurol Neurosurg Psychiatry. 2021 Mar 9. pii: jnnp-2020-325676.
    >> Share

  117. MURPHY OC, Mukharesh L, Salazar-Camelo A, Pardo CA, et al
    Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis.
    J Neurol Neurosurg Psychiatry. 2021 Mar 9. pii: jnnp-2020-325274.
    >> Share

    February 2021
  118. KOCH-HENRIKSEN N
    It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease.
    J Neurol Neurosurg Psychiatry. 2021 Feb 9. pii: jnnp-2020-325684.
    >> Share

    January 2021
  119. BURON MD, Kalincik T, Sellebjerg F, Sorensen PS, et al
    Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2021 Jan 12. pii: jnnp-2020-324869.
    >> Share

  120. PREZIOSA P, Bouman PM, Kiljan S, Steenwijk MD, et al
    Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Jan 12. pii: jnnp-2020-324391.
    >> Share

    November 2020
  121. WIJBURG MT, Warnke C, McGuigan C, Koralnik IJ, et al
    Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications.
    J Neurol Neurosurg Psychiatry. 2020 Nov 23. pii: jnnp-2020-324534.
    >> Share

  122. CUNNIFFE N, Vuong KA, Ainslie D, Baker D, et al
    Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Nov 12. pii: jnnp-2020-324286.
    >> Share

  123. KEIR LHM, Breen DP
    REM sleep behaviour disorder in patients without synucleinopathy.
    J Neurol Neurosurg Psychiatry. 2020;91:1239-1240.
    >> Share

    October 2020
  124. ZHUKOVSKY C, Sandgren S, Silfverberg T, Einarsdottir S, et al
    Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study.
    J Neurol Neurosurg Psychiatry. 2020 Oct 26. pii: jnnp-2020-323992.
    >> Share

  125. ANNUNZIATA P
    More time, more safety: is this the future optimal way for natalizumab treatment in multiple sclerosis?
    J Neurol Neurosurg Psychiatry. 2020 Oct 21. pii: jnnp-2020-324032.
    >> Share

  126. CHISARI CG, Grimaldi LM, Salemi G, Ragonese P, et al
    Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Oct 14. pii: jnnp-2020-323472.
    >> Share

    June 2020
  127. BUTZKUEVEN H, Kappos L, Wiendl H, Trojano M, et al
    Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
    J Neurol Neurosurg Psychiatry. 2020;91:660-668.
    >> Share

    May 2020
  128. PREZIOSA P, Rocca MA, Pagani E, Storelli L, et al
    Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    J Neurol Neurosurg Psychiatry. 2020;91:493-502.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016